Introduction: The identification of risk factors of recurrence of skull base meningiomas remains an important goal in neurosurgery. The purpose of the research is outcome analysis of surgical treatment and reliable prognosis scale designing.
Methods: A total of 325 patients with skull base meningiomas were studied. Each patient underwent surgery between 1996 and 2015. The mean patient age was 51.8 years. Clinical data, magnetic resonance imaging studies, angiographic data, operative reports, histological findings were examined in patients. Mean follow-up was 76 months (6-18 months). Functional outcomes were determined using the KPS.
Results: Total removal was obtained in 271 patients (83.4%); subtotal was achieved in 31 patients (9.5%). In the 325 patients, mean preoperative and follow-up Karnofsky performance scale (KPS) scores were 75.9±7 and 83±5 respectively. The median MIB-1 index was 2.7% (range: 0-41.6%). 31 patients (9.5%) had tumor regrowth. As predictors of meningiomas regrowth we define the following: earlier radiation therapy, tumor localization, tumor size, cranial nerve affection, brain invasion, grade of tumor removal, histological structure of tumor and MIB-1 index. As a result we offer numerical recurrence rate scale of meningiomas: low recurrence rate – 0-3 score, moderate – 4-6 score, high – more than 7.
Conclusions: The identification of predictors and predicting the probability of recurrence of skull base meningiomas allows choosing the correct combination of treatment options. Combined therapy is indicated for patients with high recurrence rate: microsurgery with following radiosurgery.
Patient Care: The identification of predictors and predicting the probability of recurrence of skull base meningiomas allows choosing the correct combination of treatment options.
Learning Objectives: The purpose of the research is outcome analysis of surgical treatment and reliable prognosis scale designing.
References: 1. Nakamura M, Samii M. Surgical management of a meningioma in the retrosellar region. Acta Neurochir (Wien) 2003;145:215–219.
2. Torp S H, Lindboe C F, Grønberg B H, Lydersen S, Sundstrøm S. Prognostic significance of Ki-67/MIB-1 proliferation index in meningiomas. Clin Neuropathol. 2005;24:170–174.
3. Roser F, Samii M, Ostertag H, Bellinzona M. The Ki-67 proliferation antigen in meningiomas: experience in 600 cases. Acta Neurochir (Wien) 2004;146:37–44. discussion 44.
4. Louis D N, Sheithauer B W, Budka H, Von Deimling A, Kepes J J. In: Kluihues P, Cavenee WK, editor. Pathology and Genetics of Tumors of the Nervous System. Lyon, France: IARC Press; 2000. Meningiomas. pp. 176–189.
5. Mirimanoff R O, Dosoretz D E, Linggood R M, Ojemann R G, Martuza R L. Meningioma: analysis of recurrence and progression following neurosurgical resection. J Neurosurg. 1985;62:18–24.
6. Christensen D, Laursen H, Klinken L. Prediction of recurrence in meningiomas after surgical treatment: a quantitative approach. Acta Neuropathol. 1983;61:130–134.
7. Al-Mefty O, Kadri P A, Pravdenkova S, Sawyer J R, Strangeby C, Husain M. Malignant progression in meningioma: documentation of a series and analysis of cytogenic findings. J Neurosurg. 2004;101:210–218.
8. Mahmood A, Quereshi N H, Malik G M. Intracranial meningiomas: analysis of recurrence after surgical treatment. Acta Neurochir (Wien) 1994;126:53–58.
9. Mathiesen T, Lindquest C, Kihlstyrom L, Karlsson B. Recurrence of cranial base menigiomas. Neurosurgery. 1996;39:2–7.
10. De Jesus O, Sekhar L N, Parikh H K, et al. Long-term follow-up of patients with meningiomas involving the cavernous sinus: recurrence, progression and quality of life. Neurosurgery. 1996;39:915–920.
11. Couldwell W T, Fukushima T, Gionnotta S L, et al. Petroclival meningiomas: surgical experience in 109 cases. J Neurosurg. 1996;84:20–28.
12. DeMonte F, Smith H K, Al-Mefty O. Outcome of aggressive removal of cavernous sinus meningiomas. J Neurosurg. 1994;81:245–251.
13. Ayerbe J, Lobato R D, de la Cruz J, et al. Risk factors predicting recurrence in patients operated on for intracranial meningioma: a multivariate analysis. Acta Neurochir (Wien) 1999;141:921–932.
14. Tao W, Zhimin W, Xianhaou Y, Weiguo C. Multivariate analysis of recurrence in meningioma. The Chinese-German Journal of Clinical Oncology. 2005;4:26–29.
15. Nakasu S, Nakajima M, Matsumura K I, Nakasu Y, Handa J. Meningioma: proliferating potential and clinicoradiological features. Neurosurgery. 1995;37:1049–1055.
16. Langford L A, Cooksley C S, DeMonte F. Comparison of MIB-1 (Ki-67) antigen and bromodeoxyuridine proliferation indices in meningiomas. Hum Pathol. 1996;27:350–354.
17. Prayson R A. Malignant meningioma: a clinicopathologic study of 23 patients including MIB-1 and p53 immunohistochemistry. Am J Clin Pathol. 1996;105:719–726.
18. Lanzafame S, Torrisi A, Barbagallo G, et al. Corrrelation between histological grade, MIB-1, and recurrence in 69 completely resected primary intracranial meningiomas with a 6-year mean follow-up. Pathol Res Pract. 2000;196:483–488.
19. Vannemreddy P, Nanda A, Fowler M, Nordberg M L. Skull Base Meningiomas: Do They Have a Higher Proliferation Potential for Aggression? Phoenix, AZ: Paper presented at: North American Skull Base Society Annual Meeting; February 16–19, 2006.
20. Wigertz A, Lonn S, Mathiesen T, Ahlbom A, Hall P, Feychting M., Swedish Interphone Study Group. Risk of brain tumors associated with exposure to exogenous female sex hormones. Am J Epidemiol. 2006;164:629–636.
21. Anil Nanda, Prasad Vannemreddy. Recurrence and Outcome in Skull Base Meningiomas: Do They Differ from Other Intracranial Meningiomas? Skull Base. 2008 July; 18(4): 243–252